Hyderabad-based Hetero Drugs and Dr Reddy’s Laboratories (DRL) have signed a non-exclusive, royalty-free voluntary licensing agreement with Gilead Sciences Ireland UC to manufacture and distribute lenacapavir, a breakthrough HIV treatment drug, in 120 primarily low- and lower-middle-income countries (LMICs), including India.
Lenacapavir is a USFDA-approved drug indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection, failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations. Additionally, lenacapavir is currently under investigation for the prevention of HIV (PrEP), which is yet to be approved globally.
Gilead Sciences first launched lenacapavir under the brand name Sunlenca in the US and European markets in 2022. It is a first-in-class HIV-1 capsid inhibitor.
“Lenacapavir marks an important milestone for Dr Reddy’s in patient access and affordability for pre- and post-exposure treatment of HIV. The collaboration with Gilead will help us make this latest treatment option available to patients in 120 primarily low- and lower-middle-income countries, including India. Many of these countries have a very high disease burden of HIV. This is an important endeavour in our journey to create impact on 1.5 billion patients by 2030,” said Mr. Deepak Sapra, CEO, API and Services, DRL, said.
Broadened access
Gilead's price for lenacapavir in high-income countries is $42,250 annually, but researchers estimate Indian suppliers could produce the drug for as little as $100 per person per year, with further reductions possible as demand increases.
“For over three decades, Hetero has been at the forefront of the global fight against HIV/AIDS, pioneering affordable, life-saving treatments where the need is greatest. With over 30 combinations addressing nearly 40 per cent of the global HIV/AIDS population, we take immense pride in the positive impact our efforts have made so far. We will further bring quick access to lenacapavir in Africa, India, and other LMICs, where we’ve been a cornerstone of HIV/AIDS care,” said Mr. Vamsi Krishna Bandi, Managing Director, Hetero Group of Companies.
Earlier this month, Gilead announced promising results from a pivotal Phase 3 clinical trial. The interim analysis demonstrated that lenacapavir reduced HIV infections by 96% compared to the background HIV incidence. This highlights the transformative potential of lenacapavir as a long-acting treatment and prevention option.
Further, lenacapavir is also being studied as a long-acting HIV prevention drug in ongoing clinical trials. This drug’s long-acting version can be administered every six months via a subcutaneous injection, following an initial oral loading dose.


8 October, 2024 17:03:38 IST 

















